Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed July 2026
Key Takeaways
- No direct head-to-head randomized trials of ATTR-CM disease-modifying therapies have been completed; the evidence base is separate placebo-controlled trials.
- Comparative signal is most useful for refining expectations, not for declaring a single universal winner across the disease spectrum.
- Apparent differences are highly sensitive to endpoint choice, baseline severity, and follow-up length.
- Comparison should be read alongside feasibility, persistence, and disease stage rather than in isolation.
Why ATTR-CM Has Comparative Signal But No Direct Head-to-Head Data
ATTR-CM has comparative signal without head-to-head data because its pivotal therapies were each studied against placebo, not against one another. Tafamidis was tested in ATTR-ACT and acoramidis in ATTRibute-CM, which were two separate randomized trials with different populations, eras, and outcome definitions. Reading those trials side by side is informative, but it isn't the same as a randomized comparison, and this distinction is important when interpreting comparative efficacy. The broader picture sits in the ATTR-CM therapeutic landscape.
How Endpoint Choice Changes the Apparent Comparison
The interpretation of cross-trial comparisons is influenced by the endpoints selected for analysis. The same therapy may appear to perform differently depending on whether outcomes are assessed using first-event analyses, cumulative cardiovascular events, functional measures, or mortality. Cumulative-event analyses may provide additional insight into the overall disease burden beyond what’s captured by first-event endpoints alone. Furthermore, differences in baseline disease severity, follow-up duration, and background therapy can influence observed outcomes. Consequently, findings from separate trials should be interpreted with caution and should not be considered evidence of treatment superiority.
Why Feasibility and Persistence Belong in the Comparison
Treatment feasibility and long-term treatment persistence are important considerations when interpreting comparative evidence because a therapy can only show benefit while the treatment is maintained. Real-world Medicare data provide insights into treatment adherence that should be considered when interpreting treatment effectiveness in routine clinical practice. In addition, specialty amyloidosis centers emphasize continuity of follow-up as an integral component of long-term disease management. Comparative assessments that do not consider treatment access, tolerability, and sustained treatment exposure may not fully reflect outcomes in routine clinical practice. The contribution of real-world evidence to treatment evaluation is discussed in the real-world evidence section.
What Comparative Evidence Can and Cannot Settle
Comparative evidence can inform clinical decision-making, but it can't provide definitive treatment rankings. Tafamidis and acoramidis can be discussed against each other, but interpretation still has to be grounded in disease stage, treatment feasibility, and the likelihood of sustained persistence rather than in a ranking the trials were never designed to produce. Overall, current evidence supports cautious interpretation of cross-trial comparisons. Current evidence is better at clarifying which differences matter than at establishing a universal treatment hierarchy, a theme it shares with the landmark ATTR-CM evidence.
Frequently Asked Questions
Are there direct head-to-head trials of ATTR-CM therapies?
No. The disease-modifying therapies were studied in separate placebo-controlled trials, not in randomized comparisons against each other, so there's no completed head-to-head dataset to rank them.
Why can cross-trial comparisons mislead?
Cross-trial comparisons can mislead because trials differ in population severity, endpoint definitions, follow-up length, and background care. Those differences can create apparent separation that reflects study design rather than a true difference in effect.
Can a modest comparative difference still be clinically meaningful?
Yes. In a disease where slowing disease progression is a primary treatment goal, even modest differences in treatment effect may be clinically meaningful. However, such differences should support individualized treatment decisions rather than be interpreted as evidence of overall treatment superiority.
Part of the Spotlight On ATTR-CM resource center.
References:
- ATTR-ACT: Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. New England Journal of Medicine
- ATTRibute-CM: Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. New England Journal of Medicine
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- Effect of acoramidis on recurrent and cumulative cardiovascular outcomes in ATTR-CM (ATTRibute-CM exploratory analysis). Journal of the American College of Cardiology
- Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with ATTR-CM and/or receiving tafamidis prescriptions. Journal of Managed Care & Specialty Pharmacy
- Best Practices in Specialized Amyloidosis Centers in the United States. Clinical Medicine Insights: Cardiology
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.